SAN
DIEGO, June 3, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell
therapy and genetic medicines company advancing differentiated
non-viral treatments for patients with cancer and rare diseases,
today announced that its virtual Annual Meeting of Stockholders
(the "Annual Meeting") will be held on Monday, June 17, 2024 at 1:00 p.m. PT.
The Annual Meeting will be held through a live webcast.
Stockholders of record at the close of business on April 18, 2024 are entitled to vote in the Annual
Meeting.
As provided in the Company's proxy materials, an online portal
is available to stockholders at
https://www.proxydocs.com/PSTX where stockholders can view and
download the Company's proxy materials and 2023 Annual Report in
advance of the Annual Meeting. Stockholders may also submit
questions and vote their shares prior to the Annual Meeting by
following the instructions available on the Annual Meeting
website.
To be admitted to the Annual Meeting, stockholders must register
by 8:00 p.m. PT on June 14, 2024 at https://www.proxydocs.com/PSTX.
To register, stockholders must enter the control number found on
the proxy card in the materials sent to stockholders. After
registration is complete, further instructions including a unique
link to access the virtual Annual Meeting will be emailed. Poseida
encourages stockholders to access the Annual Meeting prior to the
start time in order to allow ample time for check-in
procedures.
Below are additional details on how stockholders can participate
in the virtual Annual Meeting:
- Access the Annual Meeting website beginning at 12:45 p.m. PT on June 17,
2024.
- Vote during the Annual Meeting by following the instructions
available on the Annual Meeting website.
- Submit a question in advance of the meeting by visiting the
Annual Meeting website and entering the stockholder's control
number.
Whether or not a stockholder plans to attend the virtual-only
Annual Meeting, Poseida Therapeutics urges each stockholder to vote
and submit their proxy in advance of the meeting by one of the
methods described in the proxy materials.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated allogeneic cell therapies and genetic medicines with
the capacity to cure certain cancers and rare diseases. The
Company's pipeline includes investigational allogeneic CAR-T cell
therapies for both solid tumors and hematologic cancers as well as
investigational in vivo genetic medicines that address patient
populations with high unmet medical need. The Company's approach is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™
Site-Specific Gene Editing System, Booster Molecule and
nanoparticle gene delivery technologies, as well as in-house GMP
cell therapy manufacturing. The Company has formed strategic
collaborations with Roche and Astellas to unlock the promise of
cell therapies for cancer patients. Learn more at
www.poseida.com and connect with Poseida on X and
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-virtual-2024-annual-meeting-of-stockholders-302161982.html
SOURCE Poseida Therapeutics, Inc.
